zoapatanol: an isomer of montanol found in MONTANOA plant genus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Montanoa | genus | A plant genus of the family ASTERACEAE. Steroidal activity has been observed in animals. Members of this genus contain sesquiterpene lactones such as tomentosin, OXEPINS such as zoapatanol, and kaurene type DITERPENES.[MeSH] | Asteraceae | A large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 5281402 |
| CHEBI ID | 10123 |
| SCHEMBL ID | 7774563 |
| SCHEMBL ID | 7774561 |
| MeSH ID | M0408737 |
| Synonym |
|---|
| zoapatanol |
| 71117-51-6 |
| C09205 |
| (6r)-9-[(2s,3r,6e)-3-hydroxy-6-(2-hydroxyethylidene)-2-methyloxepan-2-yl]-2,6-dimethylnon-2-en-5-one |
| CHEBI:10123 |
| SCHEMBL7774563 |
| SCHEMBL7774561 |
| Q27108594 |
| 9-((2s,3r,6e)-3-hydroxy-6-(2-hydroxyethylidene)-2-methyl-2-oxepanyl)-2,6-dimethyl-2-nonen-5-one |
| zoapatanol [mi] |
| 3-nonen-5-one, 9-(3-hydroxy-6-(2-hydroxyethylidene)-2-methyl-2-oxepanyl)-2,6-dimethyl-, (2s-(2.alpha.(s*),3.beta.,6e))- |
| Excerpt | Relevance | Reference |
|---|---|---|
| " In pregnant beagle dogs, a dose-related contragestational effect was obtained within several days after oral administration of ORF 13811 in the dosage range of 10 to 30 mg/kg." | ( Antifertility activity and general pharmacological properties of ORF 13811: a synthetic analog of zoapatanol. Hahn, DW; McGuire, JL; Rosenthale, ME; Tobia, AJ, 1984) | 0.48 |
| Class | Description |
|---|---|
| sesquiterpenoid | Any terpenoid derived from a sesquiterpene. The term includes compounds in which the C15 skeleton of the parent sesquiterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||